X4 Pharmaceuticals (XFOR) FY2025 10-K Risk Factors: 13 New, 14 Dropped

What the changes say

X4 Pharmaceuticals restructured operations, reducing headcount by 50% in September 2025 to focus on the 4WARD Phase 3 trial for mavorixafor in congenital neutropenia.

What changed since the prior 10-K

New

NewRisks Related to Development of Our Product Candidates
We depend almost entirely on the success of our future product candidate, mavorixafor. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor for disorders other than WHIM, including CN, or any other product candidate
We depend almost entirely on mavorixafor and XOLREMDI, and may fail to expand commercial approval to disorders like chronic neutropenia.
NewRisks Related to Development of Our Product Candidates
We depend on license agreements with Genzyme and others to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidates
Termination of our license agreements with Genzyme and others could prevent us from developing or commercializing mavorixafor.
NewRisks Related to the Marketing and Commercialization of Our Product Candidates
The occurrence of any event or penalty described above, or any other sanction by a regulatory authority or other governmental entity, may inhibit our ability to commercialize our products and generate revenue
Regulatory penalties or sanctions may inhibit our ability to commercialize products and generate revenue.
NewRisks Related to the Marketing and Commercialization of Our Product Candidates
The laws and regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary
Foreign pricing regulations and varying approval requirements may delay commercial launches and negatively impact revenues for mavorixafor.
NewRisks Related to Government Regulation
may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products
Government actions to lower drug prices and changes to orphan drug exemptions under federal legislation may reduce our revenues and profitability.
NewRisks Related to Our Dependence on Third Parties
We have limited experience manufacturing our product or product candidates on a large clinical or commercial scale and
We rely on a single third-party manufacturer for the active pharmaceutical ingredient and finished capsules of mavorixafor without alternate suppliers.
NewRisks Related to Our Dependence on Third Parties
generated in our clinical trials or a specific site may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications
Unreliable clinical data or poor performance by third-party contract research organizations (CROs) could delay or prevent regulatory approval for our product candidates.
NewRisks Related to Our Intellectual Property
If we are unable to protect our intellectual property rights, our competitive position could be harmed
Our competitive position depends on uncertain patent protection and trade secrets for our proprietary technology.
NewRisks Related to Our Intellectual Property
property by our licensors and us and our partners; and
Complex interpretations of third-party licensing agreements or intellectual property disputes could narrow our rights or increase financial obligations.
NewRisks Related to Our Intellectual Property
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign
Enforcing intellectual property rights in foreign jurisdictions or adapting to Europe's new Unitary Patent System may involve substantial costs.
NewRisks Related to Our Business Operations, Employee Matters and Managing Growth
We may experience difficulties in managing the reduction in size of our organization due to our restructuring activities, and we may not achieve the expected benefits of such activities
The September 2025 restructuring implemented a 50% headcount reduction and closed our Vienna facility, which may cause management difficulties.
NewRisks Related to Our Business Operations, Employee Matters and Managing Growth
We may not realize, in full or in part, the anticipated benefits, savings and improvements from the September 2025
We may fail to realize anticipated cost savings from our 2025 restructurings and our remaining resources may prove inadequate to support future operations.
NewRisks Related to Our Business Operations, Employee Matters and Managing Growth
We may be subject to adverse legislative or regulatory changes in tax laws that could negatively impact our financial condition

Dropped

DroppedRisks Related to Our Financial Position and Need for Additional Capital
Our operating plan and liquidity position will require substantial additional funding. Our history of recurring losses and
DroppedRisks Related to Our Financial Position and Need for Additional Capital
We may be forced to delay or reduce the scope of our development programs and/or limit or cease our operations if we are unable to obtain additional funding to support our current operating plan
DroppedRisks Related to Our Financial Position and Need for Additional Capital
debt facility with Hercules contains a minimum cash financial covenant. If we default on such indebtedness, with Hercules or a future lender, we could be required to pledge additional assets, or the lenders could enforce remedies on the current collateral
Going concern doubts regarding liquidity and ability to raise capital.
DroppedRisks Related to Development of Our Product Candidates
If we fail to comply with any of our obligations under the Genzyme license agreement, or we are subject to a bankruptcy, Genzyme may have the right to terminate the license agreement, in which event we would not be able to market any product candidates covered by the license
Risk of forced delay or reduction of development programs due to lack of funding.
DroppedRisks Related to the Marketing and Commercialization of Our Product Candidates
studies or post-market surveillance. Progress reports are required at quarterly intervals, every six months and at annual intervals depending upon the country, and more frequently if serious adverse events occur
Hercules debt facility minimum cash covenant default risks.
DroppedRisks Related to the Marketing and Commercialization of Our Product Candidates
Any products that we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business
DroppedRisks Related to the Marketing and Commercialization of Our Product Candidates
country. Adverse pricing limitations may hinder our ability to recoup our investment in XOLREMDI or future product candidates, even if those candidates obtain marketing approval
DroppedRisks Related to Our Intellectual Property
We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection
DroppedRisks Related to Our Intellectual Property
required to cease our development and commercialization of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects
DroppedRisks Related to Our Business Operations, Employee Matters and Managing Growth
We will need to scale the size of our organization, and we may experience difficulties in managing this reduction in size
Risk of Genzyme license termination upon breach or bankruptcy.
DroppedRisks Related to Our Business Operations, Employee Matters and Managing Growth
As noted above, the Hercules Loan Agreement also requires that we maintain a minimum level of cash of greater than 20% of our outstanding borrowings under the Hercules Loan Agreement and subject to certain operational covenants
DroppedRisks Related to Ownership of Our Common Stock
The notification has no immediate effect on the listing of our common stock on Nasdaq
DroppedRisks Related to Ownership of Our Common Stock
consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock
DroppedRisks Related to Ownership of Our Common Stock
We may become involved in securities class action litigation or shareholder derivative litigation that could divert management’s attention and harm our business and insurance coverage may not be sufficient to cover all costs and damages

Reworded

98% rewrittenRisks Related to Ownership of Our Common Stock
Although we are currently in compliance with the Nasdaq continued listing requirements, if we are unable to maintain compliance with Nasdaq’s listing requirements, our securities could be delisted, which could affect our common stock’s market price and liquidity and reduce our ability to raise capital
Updated Nasdaq listing compliance disclosures to reflect current Bid Price Rule requirements and procedures for potential delisting.
Was: We are currently not in compliance with the Nasdaq continued listing requirements. If we are unable to regain compliance with Nasdaq’s listing requirements, our securities could be delisted, which could affect our common stock’s market price and liquidity and reduce our ability to raise capital
87% rewrittenRisks Related to Government Regulation
Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product or product candidates and affect the prices we may obtain
Refined language regarding how future healthcare legislation may increase approval costs and affect product pricing.
77% rewrittenRisks Related to Development of Our Product Candidates
If the commercial opportunity for mavorixafor in chronic neutropenic disorders is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of these diseases may be adversely affected and our business may suffer
Shifted focus from general funding risks to the specific commercial market opportunity and target patient population for mavorixafor in chronic neutropenia.
Was: If the commercial opportunity for mavorixafor in WHIM syndrome and other chronic neutropenic disorders is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of these diseases may be adversely affected and our business may suffer
77% rewrittenRisks Related to Our Financial Position and Need for Additional Capital
Changes in estimates regarding fair value of intangible assets may result in an adverse impact on our results of operations
Updated goodwill impairment language to specify that stock price declines may result in a significant impairment charge.
76% rewrittenRisks Related to the Marketing and Commercialization of Our Product Candidates
Even though we have obtained FDA approval for one of our product candidates, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business
Clarified that obtaining FDA approval for XOLREMDI does not ensure successful foreign regulatory approvals.
Was: Even though we have obtained approval for one of our product candidates from the FDA, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business
75% rewritten
Summary of Selected Risks Associated with Our Business
Updated summary risk factors to emphasize substantial funding requirements and going concern doubts until profitability is achieved.
69% rewrittenRisks Related to Our Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
Maintained standard disclosures regarding the prohibitive costs of global patent filings and foreign enforcement challenges.
67% rewrittenRisks Related to Our Financial Position and Need for Additional Capital
We have incurred significant losses and have not generated significant revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability
Updated historical net loss figures, reporting a net loss of $79.2 million for fiscal year 2025.
64% rewrittenRisks Related to Ownership of Our Common Stock
Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline
60% rewrittenRisks Related to Development of Our Product Candidates
We may develop mavorixafor, and future product candidates, in combination with other therapies, which could expose us to additional risks
Was: We may develop mavorixafor, and potentially future product candidates, in combination with other therapies, which could expose us to additional risks
46% rewrittenRisks Related to Our Intellectual Property
If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business
30% rewrittenRisks Related to Our Business Operations, Employee Matters and Managing Growth
Our term loan contains restrictions that limit our flexibility in operating our business
28% rewrittenRisks Related to Ownership of Our Common Stock
We do not anticipate that we will pay any cash dividends in the foreseeable future
26% rewrittenRisks Related to the Marketing and Commercialization of Our Product Candidates
We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do

All 62 risk factors

Headings as the filing states them, in filing order.

Other

01Summary of Selected Risks Associated with Our Business75% rewritten

Risks Related to Our Financial Position and Need for Additional Capital

02We have incurred significant losses and have not generated significant revenue from product sales since our inception. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability67% rewritten
03Changes in estimates regarding fair value of intangible assets may result in an adverse impact on our results of operations77% rewritten

Risks Related to Development of Our Product Candidates

04We have not generated significant revenues from product sales since inception and may never become profitable. We may never be able to generate meaningful revenues from sales of our product candidates and approved commercial products at levels or on timing necessary to support our investment and goals
05If the commercial opportunity for mavorixafor in chronic neutropenic disorders is smaller than we anticipate, our potential future revenue from mavorixafor for the treatment of any of these diseases may be adversely affected and our business may suffer77% rewritten
06We depend almost entirely on the success of our future product candidate, mavorixafor. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, mavorixafor for disorders other than WHIM, including CN, or any other product candidateNew
07We may develop mavorixafor, and future product candidates, in combination with other therapies, which could expose us to additional risks60% rewritten
08We depend on license agreements with Genzyme and others to permit us to use patents and patent applications. Termination of these rights or the failure to comply with obligations under these agreements could materially harm our business and prevent us from developing or commercializing our product candidatesNew
09The results of clinical trials may not support our product candidate claims
10Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal
11We may fail to enroll a sufficient number of patients in our clinical trials in a timely manner, which could delay or prevent clinical trials of our product candidates
12Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials
13Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data

Risks Related to the Marketing and Commercialization of Our Product Candidates

14The occurrence of any event or penalty described above, or any other sanction by a regulatory authority or other governmental entity, may inhibit our ability to commercialize our products and generate revenueNew
15The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, we may become subject to significant liability
16Our commercial success depends upon attaining significant market acceptance of our approved product or product candidates, if approved, among hospitals, physicians, patients and healthcare payors
17If we are unable to maintain effective sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product or product candidates, we may not be successful in commercializing our product candidates that have been approved
18We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do26% rewritten
19Even though we have obtained FDA approval for one of our product candidates, we may never obtain approval for our product candidates outside of the United States, which would limit our market opportunities and could harm our business76% rewritten
20If we seek approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could harm our business
21The laws and regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products varyNew
22Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any
23Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop

Risks Related to Government Regulation

24Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product or product candidates and affect the prices we may obtain87% rewritten
25may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our productsNew

Risks Related to Our Dependence on Third Parties

26We have limited experience manufacturing our product or product candidates on a large clinical or commercial scale andNew
27generated in our clinical trials or a specific site may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applicationsNew
28Disruptions in our supply chain could delay the commercial sale of our product
29Our employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
30We have established, and may seek to selectively establish in the future, collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans
31We may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates

Risks Related to Our Intellectual Property

32Recent laws and rulings by U.S. courts make it difficult to predict how patents will be issued or enforced in our industry
33Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may have a significant impact on our ability to protect our technology and enforce our intellectual property rights
34If we are unable to protect our intellectual property rights, our competitive position could be harmedNew
35We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our product candidates
36Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
37Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
38We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful
39If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business46% rewritten
40property by our licensors and us and our partners; andNew
41From time to time, we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain or we may lose certain licenses which may be difficult to replace
42Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
43Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
44Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
45We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
46We may not be able to protect our intellectual property rights throughout the world69% rewritten
47Many companies have encountered significant problems in protecting and defending intellectual property rights in foreignNew

Risks Related to Our Business Operations, Employee Matters and Managing Growth

48Our future success depends on our ability to retain executives and to attract, retain and motivate key personnel in a competitive environment for skilled biotechnology personnel
49We may experience difficulties in managing the reduction in size of our organization due to our restructuring activities, and we may not achieve the expected benefits of such activitiesNew
50We may not realize, in full or in part, the anticipated benefits, savings and improvements from the September 2025New
51The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive
52Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations
53We may be subject to adverse legislative or regulatory changes in tax laws that could negatively impact our financial conditionNew
54Our term loan contains restrictions that limit our flexibility in operating our business30% rewritten

Risks Related to Ownership of Our Common Stock

55Although we are currently in compliance with the Nasdaq continued listing requirements, if we are unable to maintain compliance with Nasdaq’s listing requirements, our securities could be delisted, which could affect our common stock’s market price and liquidity and reduce our ability to raise capital98% rewritten
56Our stock price has been and is likely to continue to be volatile and fluctuate substantially
57“Penny stock” rules may make buying or selling our securities difficult which may make our stock less liquid and make it harder for investors to buy and sell our securities
58If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
59We do not anticipate that we will pay any cash dividends in the foreseeable future28% rewritten
60Sales of a substantial number of shares of our common stock in the public market could cause our stock price to decline64% rewritten
61We are a “smaller reporting company” and cannot predict if the reduced reporting requirements applicable to smaller reporting companies will make our securities less attractive to investors
62Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management

Other X4 Pharmaceuticals 10-Ks

FY2024 10-K risk factors
63 risks
X4 Pharmaceuticals faces substantial operating losses and requires additional capital to fund its commercialization and development programs.
Filed Mar 26, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.